Click here to go to the previous page
Immunogenicity of Therapeutic Peptides: Regulatory Science Implications
Program Code:
422
Date:
Thursday, June 28, 2012
Time:
10:45 AM to 12:15 PM
EST
CHAIR
:
Jill has over 15 years of experience working in the pharmaceutical industry in clinical trial operations, project management, and laboratory science.
|
PRESENTER
(S):
Principal at Lehrman Biopharma, Russ consults to biotech and pharma. Expertise includes formulation and analysis R&D. An expert witness, entrepreneur and Adj Faculty-U of Kansas. Author of >60 pubs, presentations and patents. B.Sc. in Chem, McGill U; Ph.D. in Pharm Chem, U of Wisc-Madison.
|
Laura Salazar Fontana, FDA, United States
Ety Klinger, Proteologics, Ltd., Israel
Description
Like proteins, synthetic peptide-based non-biologic complex drugs (NBCD) are immunogenic and can be immunotoxic. This session will review causes of immunotoxicity and suggests regulatory guidelines to ensure immunologic safety of new or follow-on peptide-based NBCD.
Learning Objectives:
Identify potential for, and causes of, unwanted immunogenicity of peptide therapeutics, including non-biologic complex drugs (NBCD)
Illustrate risks of inadequate clinical/preclinical testing of immunogenic peptides
Identify guidelines for new and follow-on peptide-based NBCD approval.